Dr. Strosberg on Challenges in the Treatment of Neuroendocrine Tumors

Jonathan R. Strosberg, MD
Published Online: Wednesday, May 03, 2017



Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the challenges associated with treating neuroendocrine tumors (NETs).

Although there are many emerging therapies for NETs, there is little to no information on sequencing. Sequencing may give more information on what works best in the general population, but better predictive factors are needed in such a heterogeneous patient population.

Predictive factors are also needed to help determine which patients will best respond to immunotherapy, as it will probably be a small population, Strosberg says.
 


Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the challenges associated with treating neuroendocrine tumors (NETs).

Although there are many emerging therapies for NETs, there is little to no information on sequencing. Sequencing may give more information on what works best in the general population, but better predictive factors are needed in such a heterogeneous patient population.

Predictive factors are also needed to help determine which patients will best respond to immunotherapy, as it will probably be a small population, Strosberg says.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Medical Crossfire®: Bridging Emerging Data to Advance Treatment Planning for Hepatocellular Carcinoma: A Multidisciplinary Tumor BoardMar 31, 20182.0
Publication Bottom Border
Border Publication
x